Saturday 17 October 2026 Export RDHL’s income statement to Excel — free account

Redhill Biopharma Ltd.

RDHL Healthcare Drug Manufacturers Specialty & Generic

0.48 0.02 −4.00%

Follow RDHL

Alert me

Market cap: $4.4M
P/E: 0.0×
Fwd P/E: −5.1×
Dividend yield: —
F-score: 3/9
Altman Z: −24.39
Beneish M: −8.70
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	1	—	—	1	—	—	1

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 4.44

Revenue 30.56

Net Income (46.65)

Free Cash Flow (19.66)

Net Debt (5.16)

Current Ratio 0.34

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.08)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 372.46%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.52%

10-year low 10-year high

EV/Sales against its own 10 years 41.80%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	5	4	5
Receivables	3	3	0	—
Inventory	4	4	—	—
Other	—	—	—	—
	16	12	7	9

	2023	2024	2025	Q'26
Payables	3	1	—	1
ST’ Debt	—	—	—	—
Other	11	11	—	12
	20	22	19	26

Compound Annual Growth %

	10y	5y	3y
Sales	57.73%	(66.15%)	(83.34%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(23.24%)	(20.99%)	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0
’24	—	—	—	—	8
’23	—	—	—	—	7
’22	18	18	18	8	62
’21	21	22	22	22	86
’20	1	21	21	21	64

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(5)	—	—	(10)
’24	—	(6)	—	—	(9)
’23	—	—	—	—	(36)
’22	(4)	(17)	(6)	(2)	(29)
’21	(12)	(19)	(19)	(15)	(65)
’20	(11)	(16)	(9)	(13)	(49)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(5)	—	—	(10)
’24	—	(6)	—	—	(9)
’23	(7)	0	—	—	(36)
’22	(4)	(17)	(6)	(2)	(29)
’21	(12)	(19)	(19)	(15)	(65)
’20	(12)	(67)	(10)	(13)	(102)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.14)
’24	—	—	—	—	(6.71)
’23	—	—	—	—	92.25
’22	(300.00)	(200.00)	(560.00)	(71.30)	(1.16k)
’21	(530.00)	(620.00)	(460.00)	(500.00)	(2.10k)
’20	(490.00)	(450.00)	(500.00)	(700.00)	(2.10k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8,100.00	4,300.00	4,400.00	5,580.00	3,262.00	2,240.00	126.00	6.43	6.00	0.91	Analyst estimates 2026–2028 Powerpack
	High	16,540.00	11,250.00	11,489.00	9,200.00	11,350.00	11,520.00	3,270.00	288.00	38.50	6.80
People
People	Employees	13	74	75	155	182	201	113	53	35	13
	Revenue/emp, $m	0.01	0.05	0.11	0.04	0.35	0.43	0.55	0.12	0.23	0.02
Income, $m
Income, $m	Revenue	0	4	8	6	64	86	62	7	8	0
	Gross margin, %	100.00	46.94	66.06	64.09	42.68	42.39	46.06	47.03	60.31	100.00
	EBT	(29)	(46)	(39)	(42)	(76)	(98)	(72)	24	0	(8)
	EBT margin, %	(29,079.21)	(1,136.61)	(464.35)	(672.45)	(118.36)	(113.98)	(115.97)	366.25	4.48	(2,825.17)
	Net income	(29)	(46)	(39)	(42)	(76)	(98)	(72)	24	(8)	0
	Depreciation	0	0	0	1	2	18	8	2	1	0
Per share, $
Per share, $	Revenue	7.83	226.38	361.90	211.82	1,768.10	1,844.24	1,003.25	25.20	6.53	0.09
	Earnings	(2,300.00)	(2,600.00)	(1,700.00)	(1,400.00)	(2,100.00)	(2,100.00)	(1,157.50)	92.25	(6.71)	(0.14)
	Cash flow	(2,190.54)	(2,529.32)	(1,491.86)	(1,372.02)	(1,334.59)	(1,398.86)	(473.78)	(138.25)	(7.60)	(3.06)
	Capex	(9.30)	(66.72)	(2.51)	(6.83)	(1,477.31)	(2.47)	(3.21)	(0.04)	(0.01)	0.00
	Free cash flow	(2,199.84)	(2,596.05)	(1,494.37)	(1,378.86)	(2,811.90)	(1,401.33)	(477.00)	(138.29)	(7.61)	(3.06)
	Book value	4,860.54	2,546.05	2,215.84	2,020.27	380.88	190.86	(785.71)	7.99	(3.80)	1.35
	Shares, m	0	0	0	0	0	0	0	0	1	3
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	1,302.52	22.11	15.34	28.66	4.57	1.40	0.18	0.07	0.01	0.00
	P/B	2.14	2.01	2.50	3.00	21.21	13.52	0.00	0.65	6.27	0.00
	EV/Sales	660.25	10.86	8.97	21.65	5.40	1.95	2.86	6.14	6.35	6.50
	EV/FCF	(2.27)	(0.97)	(2.11)	(3.24)	(3.39)	(1.41)	(2.13)	(2.16)	(2.29)	(2.72)
Cash, $m
Cash, $m	Operating cash flow	(28)	(45)	(34)	(41)	(49)	(65)	(29)	(36)	(9)	(10)
	Capex	0	(1)	0	0	(54)	0	0	0	0	0
	Free cash flow	(28)	(46)	(35)	(41)	(102)	(65)	(29)	(36)	(9)	(10)
Balance, $m
Balance, $m	Working capital	62	40	46	43	(3)	8	(112)	(4)	(10)	(13)
	Total debt	—	—	—	4	83	85	115	—	—	—
	Net debt	(66)	(46)	(53)	(44)	53	47	79	(6)	(5)	(4)
	Shareholders’ equity	63	45	51	60	14	9	(48)	2	(5)	4
Returns, %
Returns, %	ROA	(41.65)	(69.24)	(64.83)	(61.98)	(59.90)	(54.09)	(42.15)	26.29	(40.24)	(1.98)
	ROIC	0.00	0.00	0.00	(169.34)	(59.26)	(90.38)	(86.85)	0.00	0.00	(1,671.30)
	ROE	(47.84)	(84.52)	(80.66)	(76.09)	(206.25)	(859.70)	362.65	(103.24)	632.59	206.75

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2022 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
INM InMed Pharmaceuticals Inc.	$7.3M	— (loss-making)	—	−26.22% (below 0%: shrinking)	n/m	−40.43% (below 0%: shrinking)	22.46%	0.00%	Compare
APUS Apimeds Pharmaceuticals US, Inc.	$6.6M	— (loss-making)	—	—	n/m	−67.94% (below 0%: shrinking)	—	0.00%	Compare
SNOA Sonoma Pharmaceuticals, Inc.	$5.5M	— (loss-making)	— (loss-making)	+59.55% (above 0%: growing)	n/m	+69.31% (above 0%: growing)	40.23%	(0.62%)	Compare
GELS Gelteq Limited	$4.6M	—	—	—	—	−40.15% (below 0%: shrinking)	—	—	Compare
RDHL Redhill Biopharma Ltd.	$4.4M	— (loss-making)	— (loss-making)	−90.32% (below 0%: shrinking)	n/m	−107.31% (below 0%: shrinking)	(7.52%)	0.00%
YCBD cbdMD, Inc.	$4.0M	41.2×	— (loss-making)	+20.55% (above 0%: growing)	n/m	+34.80% (above 0%: growing)	54.69%	(20.36%)	Compare
AKAN Akanda Corp.	$3.5M	—	—	—	—	−472.01% (below 0%: shrinking)	(197.87%)	0.00%	Compare
PRFX PainReform Ltd.	$2.6M	— (loss-making)	— (loss-making)	—	n/m	+52.56% (above 0%: growing)	0.00%	0.00%	Compare
BTAIQ BioXcel Therapeutics, Inc.	$2.3M	— (loss-making)	— (loss-making)	+51.67% (above 0%: growing)	n/m	+51.51% (above 0%: growing)	87.91%	(5,600.55%)	Compare
Median of peers	$4.3M	—	—	+36.11%	—	−2.68%	31.35%	0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

Redhill Biopharma Ltd. (RDHL) key facts

Redhill Biopharma Ltd. (RDHL) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, RDHL traded at $0.48, a market capitalization of $4.4 million.
Return on equity was 206.8% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −24.39 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.